Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated liposomal doxorubicin + docetaxel
- Development stage
- Unknown
- Lead developer
- The Fourth Hospital of Hebei Medical University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Pegylated liposomal doxorubicin + docetaxel is a combination chemotherapy regimen investigated by the Hebei Medical University Fourth Hospital for the neoadjuvant treatment of breast cancer. This regimen combines pegylated liposomal doxorubicin (PLD), an anthracycline encapsulated in a polyethylene glycol-coated liposome to minimize cardiotoxicity and enhance tumor delivery, with docetaxel, a taxane that promotes microtubule assembly and inhibits depolymerization. Doxorubicin exerts its cytotoxic effect by intercalating into DNA and inhibiting the enzyme topoisomerase II, leading to DNA strand breaks and inhibition of macromolecular synthesis. Docetaxel induces cell cycle arrest at the G2/M phase by stabilizing microtubules. The combination is designed to provide synergistic antitumor activity with a manageable safety profile in patients with locally advanced breast cancer.
- Other names
- PLD + docetaxelpegylated liposomal doxorubicin and docetaxel
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on pegylated liposomal doxorubicin + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated liposomal doxorubicin + docetaxel.